StockNews.AI
SRPT
StockNews.AI
3 days

SRPT Investors Have the Opportunity to Lead the Sarepta Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

1. Sarepta faces potential class action from investors over ELEVIDYS safety issues. 2. Investors claim management made misleading statements regarding ELEVIDYS risks. 3. Stock price has significantly dropped due to multiple patient death reports. 4. FDA is investigating acute liver failure linked to ELEVIDYS treatments. 5. Deadline for investors to join the suit is August 25, 2025.

6m saved
Insight
Article

FAQ

Why Very Bearish?

Sarepta's stock has already seen sharp declines due to the allegations related to ELEVIDYS, mirroring previous investor reactions during the trial's adverse events, which led to substantial price drops following safety concerns and FDA investigations.

How important is it?

The serious nature of the allegations and their direct impact on investor sentiment will likely continue to cause volatility in SRPT’s stock price.

Why Short Term?

The ongoing legal challenges and FDA scrutiny will likely maintain pressure on SRPT's price in the near future.

Related Companies

VRTXEXASBMRN
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Sarepta between June 22, 2023 and June 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) and reminds investors of the August 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) ELEVIDYS posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii) the severity of adverse events from ELEVIDYS treatment would cause the Company to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy’s present and expanded approvals; and (iv) as a result of the foregoing, Defendants materially misled with, and/or lacked a reasonable basis for, their positive statements. On March 18, 2025, Sarepta issued a safety update on ELEVIDYS announcing that a patient had died following treatment with ELEVIDYS. On this news, Sarepta’s stock price fell $27.81 per share, or 27.44%, to close at $73.54 per share on March 18, 2025. Then, on April 4, 2025, Sarepta disclosed that European Union member country authorities had requested that the independent data monitoring committee meet to review death announced on March 18, 2025. Sarepta simultaneously halted recruitment and dosing in some of the ELEVIDYS clinical studies. On this news, Sarepta’s stock price fell $4.18 per share, or 7.13%, to close at $54.43 per share on April 4, 2025. Next, on June 15, 2025, Sarepta disclosed a second patient had died of acute liver failure following treatment with ELEVIDYS. The Company announced it was suspending shipments of ELEVIDYS for non-ambulatory patients while Sarepta took time to evaluate trial regimens and discussed findings with regulatory authorities. Sarepta also revealed that it was pausing dosing in one of its ELEVIDYS clinical studies. On this news, Sarepta’s stock price fell $15.24 per share, or 42.12%, to close at $20.91 per share on June 15, 2025. Finally, on June 24, 2025, the United States Food and Drug Administration (“FDA”) issued a Safety Communication announcing it had received reports of two deaths and was investigating the risk of acute liver failure with serious outcomes following treatment with ELEVIDYS. The communication noted that the FDA was evaluating the need for further regulatory action. On this news, Sarepta’s stock price fell $1.52 per share, or 8.01%, to close at $17.46 per share on June 25, 2025. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Sarepta’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Sarepta Therapeutics class action, go to www.faruqilaw.com/SRPT or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6de302f4-9ced-4d2f-b401-6782e19b37d5

Related News